GB Sciences, Inc. (GBLX)
OTCMKTS · Delayed Price · Currency is USD
0.0003
0.00 (0.00%)
Mar 4, 2026, 9:30 AM EST
GB Sciences Revenue
GB Sciences had revenue of $97.24K in the quarter ending December 31, 2024. This brings the company's revenue in the last twelve months to $97.24K.
Revenue (ttm)
97.24K
Revenue Growth
n/a
P/S Ratio
1.58
Revenue / Employee
48.62K
Employees
2
Market Cap
153.72K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | - | - | - |
| Mar 31, 2023 | - | - | - |
| Mar 31, 2022 | - | - | - |
| Mar 31, 2021 | - | - | - |
| Mar 31, 2020 | - | - | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endonovo Therapeutics | 255.72K |
| Regen BioPharma | 236.56K |
| U.S. Stem Cell | 82.05K |
| Affymax | 42.00K |
| CNBX Pharmaceuticals | 40.64K |